- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07588711
Transcutaneous Auricular Vagus Nerve Stimulation as a Treatment for Neuropathic Pain Following Spinal Cord Injury
Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) as an Anti-inflammatory Strategy for the Treatment of Neuropathic Pain Following Spinal Cord Injury
Visão geral do estudo
Status
Condições
Descrição detalhada
Neuropathic pain is a common and debilitating complication following spinal cord injury (SCI) and is frequently resistant to pharmacologic treatment. Chronic neuroinflammation and reduced vagal tone are increasingly recognized contributors to persistent neuropathic pain after SCI. The vagus nerve plays a central role in immune regulation and descending pain modulation.
Transcutaneous auricular vagus nerve stimulation (taVNS) is a noninvasive neuromodulation technique that stimulates vagal afferent fibers via the external ear. Prior Health Canada-authorized trials conducted by the investigative team have demonstrated the feasibility, safety, and autonomic effects of taVNS in individuals with SCI.
This single-site, randomized, double-blind, sham-controlled pilot study will enroll 32 adults with SCI and neuropathic pain. Participants will be randomized 1:1 to receive either active or sham taVNS for 4 hours per day over a 30-day home-based intervention period. Outcomes will be assessed at baseline and immediately post-intervention. Feasibility and safety outcomes are primary, while exploratory clinical and mechanistic outcomes will inform the design of a future definitive randomized controlled trial.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: David J Allison, PhD.
- Número de telefone: 42570 519 646 6100
- E-mail: David.Allison@sjhc.london.on.ca
Estude backup de contato
- Nome: Joy Jiang
- Número de telefone: 42570 519 646 6100
- E-mail: fjiang63@uwo.ca
Locais de estudo
-
-
Ontario
-
London, Ontario, Canadá, N6C0A7
- Parkwood Institute, St Joseph's Health Care London
-
Contato:
- Joy Jiang
- Número de telefone: 42570 519 646 6100
- E-mail: fjiang63@uwo.ca
-
Contato:
- David J. Allison, PhD
- Número de telefone: 42570 519 646 6100
- E-mail: David.Allison@sjhc.london.on.ca
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- SCI of any level or severity
- 18 years of age or older
- current neuropathic pain
- on no medications or on a stable prescribed dose (no change in prior 6-weeks) of anti-inflammatory, pain medications and/or depression medications
Exclusion Criteria:
- Prone to autonomic dysreflexia
- presence of cardiovascular disease
- pacemaker or other implanted electrical device
- cerebral shunts
- epilepsy
- pregnant or attempting to become pregnant
- current wound/infection
- unstable dose of prescribed anti-inflammatory, depression, or pain medications within past 6-weeks.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Active taVNS
Participants receive active transcutaneous auricular vagus nerve stimulation delivered via the cymba conchae of the left ear using the using the tVNS R device (taVNS Technologies, Erlangen, Germany) for 4 hours per day for 30 days.
|
Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the tVNS R device (taVNS Technologies, Erlangen, Germany).
To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA (milliamps) until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA).
Pulse width will be set at 100μs (microseconds) and frequency will be set at 25Hz (Hertz).
Parameters will be set for the duration of the intervention consisting of 4 hours of daily stimulation for a period of 30 days.
|
|
Comparador Falso: Sham taVNS
Stimulation will target the ear lobe using the tVNS R device (taVNS Technologies, Erlangen, Germany) for 4 hours per day for 30 days.
Stimulation will be applied to the ear lobe in order to ensure participant feel the stimulation while avoiding activation of the vagus nerve.
|
Stimulation will target the ear lobe using the tVNS R device (taVNS Technologies, Erlangen, Germany).
To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA).
Pulse width will be set at 100μs and frequency will be set at 25Hz.
Participants will perform 4 hours of stimulation per day for a period of 30 days.
Stimulation will be applied to the ear lobe in order to ensure participant feel the stimulation while avoiding activation of the vagus nerve.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidência de eventos adversos emergentes do tratamento durante a intervenção
Prazo: 30 dias
|
Todos os eventos adversos que ocorrem durante a intervenção serão registrados durante as ligações telefônicas duas vezes por semana e/ou visitas de estudo e comparados entre as condições de taVNS ativo e taVNS simulado.
Uma descrição do evento adverso, número de eventos e número total de participantes afetados serão registrados.
|
30 dias
|
|
Success of Participant and Investigator Blinding
Prazo: Day 30
|
Blinding success will be assessed after completion of the intervention by asking participants and investigators to indicate which treatment group they believe the participant was assigned to (active taVNS or sham taVNS).
Blinding effectiveness will be quantified using the James Blinding Index, calculated separately for participants and investigators.
Blinding outcomes will be summarized descriptively.
|
Day 30
|
|
Recruitment Rate and Time to Recruit Target Sample Size
Prazo: Up to 20 months
|
Recruitment feasibility will be assessed by documenting the number and proportion of eligible individuals who consent to participate and the total time required to recruit the target sample of 32 participants.
Recruitment rate will be calculated as the percentage of eligible candidates who agree to participate.
These data will be summarized descriptively for the overall study population.
|
Up to 20 months
|
|
Retention and Attrition During the 30-Day Intervention
Prazo: 30 days
|
Retention will be assessed as the proportion of enrolled participants who complete the full 30-day intervention and post-intervention assessment.
Attrition will be recorded as the number and proportion of participants who withdraw prior to study completion.
Reasons for withdrawal or loss to follow-up will be documented where available.
Retention and attrition rates will be summarized and compared descriptively between the active taVNS and sham taVNS groups.
|
30 days
|
|
Adherence to Daily taVNS Stimulation Prescription
Prazo: 30 days
|
Adherence will be assessed using automated usage data recorded by the taVNS device and associated smartphone application.
Daily adherence will be calculated as the percentage of the prescribed 4-hour daily stimulation period completed (actual stimulation time divided by prescribed stimulation time × 100).
Overall adherence will be summarized as the mean daily adherence across the 30-day intervention period.
Adherence will be compared descriptively between the active taVNS and sham taVNS groups.
|
30 days
|
|
Acceptability with the taVNS intervention
Prazo: Day 30
|
Participant acceptability will be assessed at the end of the intervention using the Acceptability of Intervention Measure (AIM).
Acceptability scores will be summarized descriptively and compared between the active taVNS and sham taVNS conditions.
|
Day 30
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Circulating C-Reactive Protein
Prazo: Baseline and Day 30
|
Plasma concentrations of C-reactive protein (CRP) will be measured from fasting blood samples collected at baseline and at the end of the intervention.
Concentrations will be reported in milligrams per liter (mg/L), with higher values indicating greater systemic inflammation.
Change values will be calculated as post-intervention values minus baseline values and summarized descriptively between the active taVNS and sham taVNS groups.
|
Baseline and Day 30
|
|
Change in Circulating Interleukin-1 Beta
Prazo: Baseline and Day 30
|
Plasma concentrations of interleukin-1 beta (IL-1β) will be measured from fasting blood samples collected at baseline and at the end of the intervention.
Concentrations will be reported in picograms per milliliter (pg/mL), with higher values indicating greater pro-inflammatory activity.
Change values will be calculated as post-intervention values minus baseline values and summarized descriptively between the active taVNS and sham taVNS groups.
|
Baseline and Day 30
|
|
Change in Circulating Interleukin-6
Prazo: Baseline and Day 30
|
Plasma concentrations of interleukin-6 (IL-6) will be measured from fasting blood samples collected at baseline and at the end of the intervention.
Concentrations will be reported in picograms per milliliter (pg/mL), with higher values indicating greater pro-inflammatory activity.
Change values will be calculated as post-intervention values minus baseline values and summarized descriptively between the active taVNS and sham taVNS groups.
|
Baseline and Day 30
|
|
Change in Circulating Interferon Gamma
Prazo: Baseline and Day 30
|
Plasma concentrations of interferon gamma (IFN-γ) will be measured from fasting blood samples collected at baseline and at the end of the intervention.
Concentrations will be reported in picograms per milliliter (pg/mL), with higher values indicating greater pro-inflammatory activity.
Change values will be calculated as post-intervention values minus baseline values and summarized descriptively between the active taVNS and sham taVNS groups.
|
Baseline and Day 30
|
|
Change in Circulating Tumor Necrosis Factor Alpha
Prazo: Baseline and Day 30
|
Plasma concentrations of tumor necrosis factor alpha (TNF-α) will be measured from fasting blood samples collected at baseline and at the end of the intervention.
Concentrations will be reported in picograms per milliliter (pg/mL), with higher values indicating greater pro-inflammatory activity.
Change values will be calculated as post-intervention values minus baseline values and summarized descriptively between the active taVNS and sham taVNS groups.
|
Baseline and Day 30
|
|
Change in Neuropathic Pain Assessed by the Neuropathic Pain Symptoms Inventory
Prazo: Baseline and Day 30
|
Neuropathic pain severity and interference will be assessed using the Neuropathic Pain Symptoms Inventory (NPSI), a self-reported questionnaire with total scores ranging from 0 to 100, where higher scores indicate greater neuropathic pain severity and pain-related interference.
Change scores will be calculated as post-intervention values minus baseline values.
Mean changes and variability will be summarized and compared descriptively between the active taVNS and sham taVNS groups.
|
Baseline and Day 30
|
|
Change in Neuropathic Pain Assessed by the International Spinal Cord Injury Pain Basic Data Set (version 3)
Prazo: Baseline and Day 30
|
Neuropathic pain severity and pain-related interference will be assessed using the International Spinal Cord Injury Pain Basic Data Set (ISCIPBDS), version 3, which includes numeric rating scales ranging from 0 to 10, where higher scores indicate greater pain intensity and greater pain-related interference.
Change scores will be calculated as post-intervention values minus baseline values.
Mean changes and variability will be summarized and compared descriptively between the active taVNS and sham taVNS groups.
|
Baseline and Day 30
|
|
Change in Vagal Tone Assessed by Heart Rate Variability
Prazo: Baseline and Day 30
|
Vagal tone will be assessed using heart rate variability (HRV) derived from a 5-minute resting electrocardiogram recording.
Root mean square of successive differences (RMSSD) and high-frequency power will be calculated using standard HRV analysis procedures.
Change in HRV measures from baseline to post-intervention will be summarized descriptively and compared between the active taVNS and sham taVNS groups.
|
Baseline and Day 30
|
|
Change in Health-Related Quality of Life
Prazo: Baseline and Day 30
|
Quality of life will be assessed using selected short forms from the Spinal Cord Injury-Quality of Life (SCI-QOL) measurement system, including Pain Interference, Depression, and Positive Affect and Well-Being domains.
Scores will be calculated as standardized T-scores.
Change in quality-of-life scores from baseline to post-intervention will be summarized and compared descriptively between treatment groups.
|
Baseline and Day 30
|
Colaboradores e Investigadores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Dor
- Manifestações Neurológicas
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Ferimentos e Lesões
- Processos Patológicos
- Doenças Neuromusculares
- Doenças do Sistema Nervoso Periférico
- Trauma, Sistema Nervoso
- Doenças da Medula Espinhal
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Inflamação
- Neuralgia
- Lesões da Medula Espinhal
Outros números de identificação do estudo
- ALLISON-03-2026
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .